Mesenchymal Stem Cells (MSCs)

Mesenchymal stem cells (MSCs) are a well-characterized population of adult stem cells that can differentiate into a variety of cell types (chondrocytes, osteoblasts, adipocytes, myocytes, and more).

MSC Therapies | Globally Approved Mesenchymal Stem Cell Therapeutics

July 15, 2019 By Cade Hildreth (CEO) Leave a Comment

As the most common stem cell type being used within regenerative medicine, there is huge potential for growth within the mesenchymal stem cell (MSC) market. Today, MSCs are the most common stem cell type being used within clinical trials, as well as the most studied stem cell type within the scientific literature. [Read more…]

Mesoblast’s Mesenchymal Precursor Cell (MPC) Therapy Receives Orphan Drug Designation

June 24, 2019 By Cade Hildreth (CEO) Leave a Comment

Mesoblast (ASX:MSB; Nasdaq: MESO) announced that the U.S. FDA granted the company’s product candidate, Revascor, Orphan Drug Designation for prevention of gastrointestinal bleeding in patients with left ventricular assist devices.

Revascor, Mesenchymal Precursor Cells

Revascor is Mesoblast’s investigational cell therapy composed of 150 million allogeneic mesenchymal precursor cells (MPCs). [Read more…]

Cynata Completes Phase I Trial for CYP-001, Triggers Option Window for Fujifilm

December 19, 2018 By Cade Hildreth (CEO)

It is official. Australian stem cell company Cynata Therapeutics has completed the world’s first Phase I trial involving an induced pluripotent stem cell (iPSC) derived therapeutic product. The landmark study involved the company’s lead product, CYP-001, an iPSC-derived mesenchymal stem cell (MSC) product that can be manufactured at therapeutic grade and at mass scale using Cynata’s Cymerus™ platform technology.

Next, the company will be initiating Phase II trials in graft-versus-host disease (GvHD), critical limb ischemia (CLI) and osteoarthritis, showcasing the power of Cynata’s platform technology to be leveraged across multiple indications. Osteoarthritis will be Cynata’s largest clinical trial to date and also one of the largest ever for an MSC product. [Read more…]